Literature DB >> 11034269

Determination of ifosfamide, 2- and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection.

T Kerbusch1, M J Jeuken, J Derraz, J W van Putten, A D Huitema, J H Beijnen.   

Abstract

A comparison was made between methods for determining ifosfamide (IF), 2- (2DCE) and 3-dechloroethylifosfamide (3DCE) using gas chromatography with nitrogen-phosphorus detection (GC-NPD) versus positive ion electron-impact ion-trap mass spectrometry (GC-MS2). Sample pretreatment involved liquid-liquid extraction with ethyl acetate after adding trofosfamide as internal standard and alkalinization. The GC-NPD was linear, specific, and sensitive for all analytes in the range of 0.0500-100 microg/mL with lower limits of quantification (LLQ) of 0.0500 microg/mL using a 50-microgL plasma sample. The GC-MS2 was linear, specific, and sensitive for IF, 2DCE, and 3DCE in the ranges of 0.250-100, 0.500-25.0, and 0.500-25.0 microg/mL, respectively, with LLQs of 0.250, 0.500, and 0.500 microg/mL. The ranges of accuracy, within-day precision, and between-day precision for analysis of all compounds with GC-NPD did not exceed 93.3% to 105.4%, 8.0% and 9.8%, respectively. The ranges of accuracy, within-day precision, and between-day precision for analysis of all compounds with GC-MS2 did not exceed 86.5% to 99.0%, 9.0% and 12.7%, respectively. In conclusion, GC-NPD proved to be superior to GC-MS2 in sensitivity, detection range, accuracy, and precisions. Therefore GC-NPD is the method of choice for fast un-derivatized determination of IF, 2DCE, and 3DCE in human plasma, and it can readily be used for clinical pharmacokinetic studies and routine monitoring of IF-treated patients in a hospital setting.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034269     DOI: 10.1097/00007691-200010000-00018

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

2.  Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.

Authors:  T Kerbusch; J de Kraker; R A Mathĵt; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.

Authors:  T Kerbusch; G Groenewegen; R A A Mathôt; V M M Herben; W W ten Bokkel Huinink; M Swart; B Ambaum; H Rosing; S Jansen; E E Voest; J H Beijnen; J H M Schellens
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

4.  A New Method to Quantify Ifosfamide Blood Levels Using Dried Blood Spots and UPLC-MS/MS in Paediatric Patients with Embryonic Solid Tumours.

Authors:  Luz-María Torres; Liliana Rivera-Espinosa; Juan L Chávez-Pacheco; Carlos F Navas; Joel A Demetrio; Radamés Alemón-Medina; Francisca Trujillo; Martín Pérez; Martha M Zapata; Rocío Cárdenas; Citlaltepetl Salinas; Arnoldo Aquino; Rafael Velázquez-Cruz; Manuel-de-Jesús Castillejos
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.